Non-Resectable Pancreas Carcinoma
4
2
2
0
Key Insights
Highlights
Treatment Research
6 treatments under study, led by Sequential Ag And Mfolfox In Combination With Serplulimab And Bevacizumab
Research Leaders
8 sponsors active, led by Zhejiang Cancer Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
25%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (4)
Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS)
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
Research Network
Common Treatments
- Sequential Ag And Mfolfox In Combination With Serplulimab And Bevacizumab1
- Sequential Ag And Mfolfox In Combination With Serplulimab Injection And Bevacizumab Injection1
- Hifu Intervention1
- Gemcitabine1
- Ag Chemotherapy1
Active Sponsors
- Zhejiang Cancer Hospital2
- Aarhus University Hospital1
- Morten Ladekarl1
- Herlev and Gentofte Hospital1
- Gødstrup Hospital1
Top Investigators
Zhejiang Cancer Hospital
Aalborg Universitets Hospital, Department of Oncology
Related Conditions
- Pancreas Cancer1